Kaitlyn Greppin1, Gino Cioffi2, Kristin A Waite2, Quinn T Ostrom3, Daniel Landi4, Kailey Takaoka1, Carol Kruchko3, Jill S Barnholtz-Sloan2. 1. Hathaway Brown School, Science Research & Engineering Program, Shaker Heights, Ohio, USA. 2. Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA. 3. Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA. 4. The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.
Abstract
Background: Pineoblastoma (PB) is a rare malignant brain tumor originating in the pineal gland. Here, we provide a comprehensive epidemiological analysis of PB in the United States from 2000 to 2017. Methods: Data on 1133 patients with PB were acquired from the Central Brain Tumor Registry of the United States, in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, from 2000 to 2017. Age-adjusted incidence rates (AAIRs) per 100 000 and incidence rate ratios (IRRs) were reported for age, sex, race, and ethnicity. Using the National Program of Cancer Registries survival database, median survival and hazard ratios (HRs) were evaluated for overall survival from 2001 to 2016. Results: Incidence was highest in ages 0-4 years (AAIR: 0.049, 95% CI: 0.042-0.056), decreasing as age increased. Incidence was higher among patients who are Black compared to patients who are White (IRR: 1.71, 95% CI: 1.48-1.98, P < .001), and was impacted by age at diagnosis, with Black-to-White incidence highest in children ages 5-9 years (IRR: 3.43, 95% CI: 2.36-4.94, P < .001). Overall survival was lower for males (HR: 1.39, 95% CI: 1.07-1.79, P = .013). All age groups, excluding those over 40, had improved survival compared to ages 0-4 years. Those who received surgical intervention had better survival compared to those who did not receive surgical treatment. Conclusion: PB incidence is highest among children and patients who are Black, and there may be a potential interaction between these factors. Survival is worse among males, young children, and elderly adults, and those who received no surgery. Comprehensive, population-based statistics provide critical information on PB characteristics that could be useful in impacting patient care and prognosis. Published by Oxford University Press 2022.
Background: Pineoblastoma (PB) is a rare malignant brain tumor originating in the pineal gland. Here, we provide a comprehensive epidemiological analysis of PB in the United States from 2000 to 2017. Methods: Data on 1133 patients with PB were acquired from the Central Brain Tumor Registry of the United States, in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, from 2000 to 2017. Age-adjusted incidence rates (AAIRs) per 100 000 and incidence rate ratios (IRRs) were reported for age, sex, race, and ethnicity. Using the National Program of Cancer Registries survival database, median survival and hazard ratios (HRs) were evaluated for overall survival from 2001 to 2016. Results: Incidence was highest in ages 0-4 years (AAIR: 0.049, 95% CI: 0.042-0.056), decreasing as age increased. Incidence was higher among patients who are Black compared to patients who are White (IRR: 1.71, 95% CI: 1.48-1.98, P < .001), and was impacted by age at diagnosis, with Black-to-White incidence highest in children ages 5-9 years (IRR: 3.43, 95% CI: 2.36-4.94, P < .001). Overall survival was lower for males (HR: 1.39, 95% CI: 1.07-1.79, P = .013). All age groups, excluding those over 40, had improved survival compared to ages 0-4 years. Those who received surgical intervention had better survival compared to those who did not receive surgical treatment. Conclusion: PB incidence is highest among children and patients who are Black, and there may be a potential interaction between these factors. Survival is worse among males, young children, and elderly adults, and those who received no surgery. Comprehensive, population-based statistics provide critical information on PB characteristics that could be useful in impacting patient care and prognosis. Published by Oxford University Press 2022.
Authors: Michelle Dong; Gino Cioffi; Jacqueline Wang; Kristin A Waite; Quinn T Ostrom; Carol Kruchko; Justin D Lathia; Joshua B Rubin; Michael E Berens; James Connor; Jill S Barnholtz-Sloan Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-29 Impact factor: 4.254
Authors: Benjamin Farnia; Pamela K Allen; Paul D Brown; Soumen Khatua; Nicholas B Levine; Jing Li; Marta Penas-Prado; Anita Mahajan; Amol J Ghia Journal: World Neurosurg Date: 2014-07-18 Impact factor: 2.104
Authors: Matthew Tate; Michael E Sughrue; Martin J Rutkowski; Ari J Kane; Derick Aranda; Lashaun McClinton; Lashay McClinton; Igor J Barani; Andrew T Parsa Journal: Cancer Date: 2011-06-29 Impact factor: 6.860
Authors: Kara A Parikh; Garrett T Venable; Brent A Orr; Asim F Choudhri; Frederick A Boop; Amar J Gajjar; Paul Klimo Journal: Neurosurgery Date: 2017-07-01 Impact factor: 4.654
Authors: Michael C Jin; Laura M Prolo; Adela Wu; Tej D Azad; Siyu Shi; Adrian J Rodrigues; Scott G Soltys; Erqi L Pollom; Gordon Li; Susan M Hiniker; Gerald A Grant Journal: Neurosurgery Date: 2020-02-28 Impact factor: 4.654
Authors: Bryan K Li; Alexandre Vasiljevic; Christelle Dufour; Fupan Yao; Ben L B Ho; Mei Lu; Eugene I Hwang; Sridharan Gururangan; Jordan R Hansford; Maryam Fouladi; Sumihito Nobusawa; Annie Laquerriere; Marie-Bernadette Delisle; Jason Fangusaro; Fabien Forest; Helen Toledano; Palma Solano-Paez; Sarah Leary; Diane Birks; Lindsey M Hoffman; Alexandru Szathmari; Cécile Faure-Conter; Xing Fan; Daniel Catchpoole; Li Zhou; Kris Ann P Schultz; Koichi Ichimura; Guillaume Gauchotte; Nada Jabado; Chris Jones; Delphine Loussouarn; Karima Mokhtari; Audrey Rousseau; David S Ziegler; Shinya Tanaka; Scott L Pomeroy; Amar Gajjar; Vijay Ramaswamy; Cynthia Hawkins; Richard G Grundy; D Ashley Hill; Eric Bouffet; Annie Huang; Anne Jouvet Journal: Acta Neuropathol Date: 2019-12-09 Impact factor: 17.088